04/09/2007

A Review of Transdermal Hormonal Contraception: Focus on the Ethinylestradiol/ Norelgestromin Contraceptive Patch


Graziottin A.
A Review of Transdermal Hormonal Contraception: Focus on the Ethinylestradiol/ Norelgestromin Contraceptive Patch
Treatments in Endocrinology, 2006; 5 (6): 359-365

CONDIVIDI SU

Imperfect use of contraceptive methods notably increases the likelihood of pregnancy. One means of improving user adherence with hormonal contraception is to minimize the dosing schedule. Two forms of hormonal contraceptive have currently achieved this goal: the transdermal patch and the vaginal ring. The first and only transdermal contraceptive patch ro receive worldwide regulatory approval (ethinylestradiol/ norelgestromin) is a convenient approach to contraception that has a similar efficacy to oral contraceptives (OC's), but with the benefit of once-weekly administration. In addition, transdermal delivery of contraceptive hormones eliminates variability in gastrointestinal absorption, avoids hepatic first-pass metabolism, and prevents the peaks and troughs in serum concentrations that are seen with OCs.

top


Available documents:
Full text of the article (English)
Full text of the article (Italian)


By courtesy of Wolters Kluwer Health - Adis International Ltd, Italy

FAIR USE: The content of this paper can be downloaded, printed and read for strictly personal and non-profit use. Any citation for didactic and/or scientific purpose must quote the title of the document, the name of the author(s), the data of the book or journal, and the URL of the site (www.alessandragraziottin.it).

WARNING: Every therapy must be discussed, tailored, prescribed and monitored by the M.D. personally consulted. Every information presented in this website can not surrogate the personal relationship with the caring physician nor be utilized without specific medical advice.